MYD88 and COVID-19: Based on the RNA-Seq findings, we hypothesise that the Mw-mediated downregulation of the key TLR2-MYD88 pathway and its subsequent downstream signalling pathways might have contributed substantially to its efficacy terms of the absolute reduction in the development of symptomatic COVID-19 as well as the moderation of the severity of COVID-19.